Only HER2 Breast Cancer benefits from Adrymycian

[tousled1]

Results from two studies presented Thursday at the 30th annual San Antonio Breast Cancer Symposium now reveal that only women with HER2 positive breast cancer -- a subset which accounts for only about 8 percent of women with breast cancer worldwide -- will benefit significantly from standard anthracycline-based chemotherapy.

Read entire article:

http://www.abcnews.go.com/Health/OnCallPlusBreastCancerNews/story?id=4001402&page=1